Searching…
Belzutifan showed meaningful antitumour activity in VHL disease-associated CNS haemangioblastomas that was sustained for more than 3 years of treatment. These results continue to support belzutifan as …
Antitumor activity observed in the ongoing open-label phase 2 study, LITES-PARK-004 (NCT03401788), led to the approval of belzutifan for the treatment of patients (pts) with VHL disease who require …
The first-in-class hypoxia-inducible factor-2α inhibitor belzutifan showed clinically meaningful antitumour activity in von Hippel-Lindau (VHL) disease–associated neoplasms in the ongoing, single-arm, phase …
In the Kidney and Bladder Poster session at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Ramaprasad Srinivasan presented results of an ongoing open-label phase 2 …
In the phase II MK-6482-004 trial reported in The New England Journal of Medicine, Eric Jonasch, MD, and colleagues found that the hypoxia-inducible factor (HIF)-2α inhibitor belzutifan produced …
The approval was based on results of the single-arm MK-6482 study that included 61 patients overall treated with belzutifan 120 mg orally daily, including 51 with CNS HB at baseline (per investigator …
Belzutifan elicits responses in patients with renal cell carcinoma (RCC) associated with von Hippel-Lindau (VHL) disease, according to research published in The New England Journal of...
Belzutifan was investigated in the ongoing Study 004 (NCT03401788), an open-label clinical trial in 61 patients with VHL-associated RCC (VHL-RCC) diagnosed based on a VHL germline...
Now, results from a phase II trial show that the HIF2α inhibitor belzutifan has activity in RCC and other VHL -related neoplasms. A total of 61 patients with VHL disease and at least...
In this phase 2, open-label, single-group trial, we investigated the efficacy and safety of the HIF-2 α inhibitor belzutifan (MK-6482, previously called PT2977), administered orally at a dose of 120 mg …
